Timolol/brimonidine combination therapy in glaucoma management

Clinical and Surgical Ophthalmology

Volumn 23, Issue 10, 2005, Pages 356-359

  Crichton, Andrew C S ^a,b,c  

^a UNIVERSITY OF CALGARY   (Canada)

^b Rockyview General Hospital   (Canada)

^c NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BIMATOPROST; BRIMONIDINE; COMBIGAN; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST; LIPID; TIMOLOL; TIMOLOL MALEATE; TRAVOPROST;

ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; PATIENT SATISFACTION; SIDE EFFECT;

EID: 27744509245     PISSN: 17054842     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. Centofanti M, Manni G, Gregori D, et al. Comparative acute effects of brimonidine 0.2% versus dorzolamide 2% combined with beta-blockers in glaucoma. Graefe's Arch Clin Exp Ophthalmol 2000; 238: 302-305.
2. Simmons ST. Efficacy of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers in adult patients with glaucoma or ocular hypertension. Clin Ther 2001; 23: 604-619.
3. The AGIS Investigators. The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intra-ocular pressure and visual field deterioration. AM J Opthalmol 2000; 130: 429-440.
4. Lee DA. Efficacy of brimonidine as replacement therapy in patients with open-angle glaucoma or ocular hypertension. Clin Ther 2000; 22: 53-65.